A Study to Assess the Adverse Events and How Intravenously Infused Livmoniplimab in Combination With Budigalimab Moves Through the Bodies of Adult Chinese Participants With Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC)

Hepatocellular carcinoma (HCC) is a common cancer worldwide and a leading cause of cancer-related death. The majority of participants first presenting with HCC have advanced unresectable or metastatic disease. The purpose of this study is to assess adverse events and how livmoniplimab in combination with budigalimab moves through the body in adult Chinese participants with Locally Advanced or metastatic Child-Pugh A Hepatocellular Carcinoma (HCC). Livmoniplimab is an investigational drug being developed for the treatment of HCC. There are 2 stages to this study. Stage 1 is a safety run-in. Th

Trial Details

NCT ID

NCT06487559

Phase

PHASE1

Sponsor

AbbVie

Status

RECRUITING

Cancer Type

Liver Cancer

Interventions

• Livmoniplimab
• Budigalimab

Locations (sample)

• Beijing, Beijing Municipality, China|39.9075,116.39723
• Fuzhou, Fujian, China|26.06139,119.30611
• Guangzhou, Guangdong, China|23.11667,113.25
• Guangzhou, Guangdong, China|23.11667,113.25
• Harbin, Heilongjiang, China|45.75,126.65

Key Eligibility Criteria

• Locally advanced or metastatic and/or unresectable HCC
• Child-Pugh A
• Barcelona Clinic Liver Cancer stage B or C
• Eastern Cooperative Oncology Group (ECOG) Perfromance Status of 0-1

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Liver Cancer Trials on Trialify →